Milder forms of α-sarcoglicanopathies diagnosed in adulthood by NGS analysis.

J Neurol Sci

Department of Neurology, Neuromuscular Unit, 12 de Octubre University Hospital, Avda de Córdoba s/n, Madrid 28041, Spain; Research Institute of Hospital 12 de Octubre (i+12), Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain.

Published: November 2018

Introduction: Sarcoglycanopathies (LGMD 2C2F) are a subgroup of limb-girdle muscular dystrophies (LGMD), caused by mutations in sarcoglycan genes. They usually have a childhood onset and rapidly progressive course with loss of ability to walk over 12-16 years.

Methods: Next generation sequencing (NGS) targeted gene panel was performed in three adult patients with progressive muscle weakness in which routine muscle histology and immunohistochemistry were not diagnostic.

Results: Genetic analysis revealed homozygous or compound heterozygous mutations in SGCA gene and Western Blot demonstrated protein reduction confirming the diagnosis of α-sarcoglicanopathy.

Discussion: Our cases evidence that the diagnosis of mild forms of alfa sarcoglicanopathy could be a challenge and suggest the possibility that they could be underdiagnosed. The use of Next generation Sequencing targeted gene panels is very helpful in the diagnosis of these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.08.026DOI Listing

Publication Analysis

Top Keywords

generation sequencing
8
targeted gene
8
milder forms
4
forms α-sarcoglicanopathies
4
α-sarcoglicanopathies diagnosed
4
diagnosed adulthood
4
adulthood ngs
4
ngs analysis
4
analysis introduction
4
introduction sarcoglycanopathies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!